Biocryst Pharmaceuticals reported $93.27M in Operating Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
DBV Technologies DBVT:US USD 20.09M 5.26M
Alnylam Pharmaceuticals ALNY:US USD 598.93M 182.43M
Biocryst Pharmaceuticals BCRX:US USD 93.27M 6.98M
Chugai Pharma 4519:JP JPY 128.4B 7.28B
Daiichi Sankyo 4568:JP JPY 266.28B 20.35B
Enanta Pharmaceuticals ENTA:US USD 47.36M 4.65M
Gilead Sciences GILD:US USD 4.2B 26M
GlaxoSmithKline GSK:LN GBP 6.64B 790M
Glaxosmithkline GSK:US GBP 6.64B 790M
Intra Cellular Therapies ITCI:US USD 127.5M 16M
IONIS PHARMACEUT IONS:US USD 218.92M 384K
Karyopharm Therapeutics KPTI:US USD 66.98M 15.6M
Mirati Therapeutics MRTX:US USD 191.87M 9.31M
Neurocrine Biosciences NBIX:US USD 300.1M 93.4M
Novavax NVAX:US USD 861.77M 192.88M
Ptc Therapeutics PTCT:US USD 285.31M 27.43M
Regeneron Pharmaceuticals REGN:US USD 1.71B 34.8M
Roche Holding ROG:VX 20.75B 3.26B
Sarepta Therapeutics SRPT:US USD 487.06M 42.45M
Ultragenyx Pharmaceutical RARE:US USD 315.77M 84.83M
Vertex Pharmaceuticals VRTX:US USD 1.21B 117.7M
YTE INCY:US USD 684.93M 27.96M